What does OncoSil Medical Ltd do?
OncoSil Medical Ltd [ASX:OSL] has developed a patented medical treatment for pancreatic and liver cancers.
The standard treatment of care for these cancers is to provide intravenous chemotherapy and in some cases external beam radiation.
OncoSil’s treatment is different, it’s injected directly into the tumour and produces localised radiation, causing dividing cells to die. This process of killing dividing cells continues for several weeks, stopping the tumour from growing and in some cases shrinking it.
When the radioactivity is no longer produced (usually around three months) inert, non-harmful material remains in the pancreas. This localised treatment greatly reduces side effects compared to other treatments. And importantly, it increases the quality of life in pancreatic cancer patients.
Pancreatic cancer continues to pose a major threat, with 279,000 new cases diagnosed annually. The estimated total market opportunity for OncoSil in pancreatic cancer exceeds $1 billion dollars. And there is potential to apply this treatment to other solid tumours.
OncoSil is now in the process of going through the required regulatory approvals needed to break into European market. Once received, this will open up a huge potential target market.
That’s interesting, but what is the chart telling us?
What does the chart look like?
I always find it helpful to bring up a chart. Here’s the weekly chart of OSL.
The share price has just broken over weekly tops, which makes it a chart of interest. It goes into the watch list now.
What now for OSL shares?
We watch how the share price reacts to future tops and bottoms. We can use the major high of 18 cents back in 2013, as a reference point to guide any future investment decisions.
If you do not fully understand this process then you remain at a severe investment disadvantage. Go here to find out more.
Research Analyst, Cycles, Trends and Forecasts